These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8902388)

  • 1. Oncogenic proteins as tumor antigens.
    Disis ML; Cheever MA
    Curr Opin Immunol; 1996 Oct; 8(5):637-42. PubMed ID: 8902388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of melanoma antigen expression in cancer therapy.
    Gillespie AM; Coleman RE
    Cancer Treat Rev; 1999 Aug; 25(4):219-27. PubMed ID: 10448130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human tumor antigens are ready to fly.
    Henderson RA; Finn OJ
    Adv Immunol; 1996; 62():217-56. PubMed ID: 8781270
    [No Abstract]   [Full Text] [Related]  

  • 4. [Tumor antigens].
    Tiuriaeva II
    Tsitologiia; 2008; 50(3):189-209. PubMed ID: 18664121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor immunology.
    Stevenson H; Tsang KY
    Immunol Ser; 1993; 58():497-515. PubMed ID: 8424991
    [No Abstract]   [Full Text] [Related]  

  • 6. Prophylactic cancer vaccines.
    Finn OJ; Forni G
    Curr Opin Immunol; 2002 Apr; 14(2):172-7. PubMed ID: 11869888
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody Therapies in Cancer.
    Wang S; Jia M
    Adv Exp Med Biol; 2016; 909():1-67. PubMed ID: 27240456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic analysis of 63,220 tumors reveals insights into tumor uniqueness and targeted cancer immunotherapy strategies.
    Hartmaier RJ; Charo J; Fabrizio D; Goldberg ME; Albacker LA; Pao W; Chmielecki J
    Genome Med; 2017 Feb; 9(1):16. PubMed ID: 28231819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The function of tumor specific antigen (MAGE) in tumor immunotherapy].
    Fang JB; Wang L
    Sheng Li Ke Xue Jin Zhan; 2005 Jul; 36(3):273-5. PubMed ID: 16270835
    [No Abstract]   [Full Text] [Related]  

  • 10. [Tumor antigens recognized by T-lymphocytes in human cancers. New advances and therapeutic perspectives].
    Gaugler B; Olive D
    Pathol Biol (Paris); 1998 Dec; 46(10):771-8. PubMed ID: 9922993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Update on tumor immunology].
    Fridman WH; Berger A; Lee RS; Tartour E
    Bull Cancer; 1998 Jan; 85(1):29-30. PubMed ID: 9752341
    [No Abstract]   [Full Text] [Related]  

  • 12. A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.
    Neumann F; Kubuschok B; Ertan K; Schormann C; Stevanovic S; Preuss KD; Schmidt W; Pfreundschuh M
    Cancer Immunol Immunother; 2011 Sep; 60(9):1333-46. PubMed ID: 21630107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer/testis (CT) antigens: potential targets for immunotherapy.
    Caballero OL; Chen YT
    Cancer Sci; 2009 Nov; 100(11):2014-21. PubMed ID: 19719775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
    Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
    Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines.
    Klein C; Bueler H; Mulligan RC
    J Exp Med; 2000 May; 191(10):1699-708. PubMed ID: 10811863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human Tumor Antigens Yesterday, Today, and Tomorrow.
    Finn OJ
    Cancer Immunol Res; 2017 May; 5(5):347-354. PubMed ID: 28465452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?
    Shurin MR; Gregory M; Morris JC; Malyguine AM
    Expert Opin Biol Ther; 2010 Nov; 10(11):1539-53. PubMed ID: 20955111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The generation and analyses of a novel combination of recombinant adenovirus vaccines targeting three tumor antigens as an immunotherapeutic.
    Gabitzsch ES; Tsang KY; Palena C; David JM; Fantini M; Kwilas A; Rice AE; Latchman Y; Hodge JW; Gulley JL; Madan RA; Heery CR; Balint JP; Jones FR; Schlom J
    Oncotarget; 2015 Oct; 6(31):31344-59. PubMed ID: 26374823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein tumor antigens.
    Srivastava PK
    Curr Opin Immunol; 1991 Oct; 3(5):654-8. PubMed ID: 1755984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progenics, Somatix in phase III cancer vaccine trials.
    Glaser V
    Nat Biotechnol; 1996 Mar; 14(3):257, 260. PubMed ID: 9630880
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.